Viking Therapeutics and Arcutis Biotherapeutics Await Q4 Catalysts
VKTX Viking Therapeutics Inc
$26.65 -5.96%
View chart & analysis → 
- 1Viking Therapeutics will initiate Phase 3 clinical trials for VK2735 targeting obesity and type 2 diabetes patients in the fourth quarter.
- 2With 20% of Phase 2 clinical trial participants discontinuing due to adverse reactions, CEO Brian Lian stated that the Phase 3 study will reduce dosage.
- 3Arcutis Biotherapeutics is drawing attention toward the release of Phase 2 data for Zoryve foam for vitiligo treatment and an expected FDA decision in February 2027.
So what's the key point?
Viking Therapeutics is starting a new obesity treatment trial, and Arcutis Biotherapeutics is waiting for treatment results. Both companies are expected to have important results late this year or early next year.
Source The Motley Fool · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.